DE502004009453D1 - 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose - Google Patents

3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Info

Publication number: DE502004009453D1
Authority: DE; Germany
Prior art keywords: cyclohexancarbonyl; ylmethoxy; oxazole; atherosclerosis; diabetes
Prior art date: 2003-02-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE502004009453T

Other languages

English (en)

Inventor

Christian Stapper

Dirk Gretzke

Eugen Falk

Jochen Goerlitzer

Stefanie Keil

Hans-Ludwig Schaefer

Heiner Glombik

Wolfgang Wendler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis Deutschland GmbH

Original Assignee

Sanofi Aventis Deutschland GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-19

Publication date

2009-06-18

2004-02-19 Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH

2009-06-18 Publication of DE502004009453D1 publication Critical patent/DE502004009453D1/de

2024-02-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

CTRGJRGBKLRHPE-UHFFFAOYSA-N 3-methyl-2-[[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexanecarbonyl]amino]butanoic acid Chemical class C1C(C(=O)NC(C(C)C)C(O)=O)CCCC1OCC1=COC(C=2C=CC=CC=2)=N1 CTRGJRGBKLRHPE-UHFFFAOYSA-N 0.000 title 1
201000001320 Atherosclerosis Diseases 0.000 title 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

DE502004009453T 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose Expired - Lifetime DE502004009453D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001578 WO2004076426A1 (de)	2003-02-27	2004-02-19	3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number	Publication Date
DE502004009453D1 true DE502004009453D1 (de)	2009-06-18

Family

ID=32920629

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DE10308355A Withdrawn DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE502004004139T Expired - Lifetime DE502004004139D1 (de)	2003-02-27	2004-02-19	3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009453T Expired - Lifetime DE502004009453D1 (de)	2003-02-27	2004-02-19	3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE502004009690T Expired - Lifetime DE502004009690D1 (de)	2003-02-27	2004-02-19	4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE10308355A Withdrawn DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE502004004139T Expired - Lifetime DE502004004139D1 (de)	2003-02-27	2004-02-19	3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy -essigsäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE502004009690T Expired - Lifetime DE502004009690D1 (de)	2003-02-27	2004-02-19	4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Country Status (34)

Country	Link
US (5)	US7259177B2 (de)
EP (3)	EP1599455B1 (de)
JP (3)	JP2006519194A (de)
KR (3)	KR20050105492A (de)
CN (3)	CN100439345C (de)
AR (3)	AR043433A1 (de)
AT (3)	ATE430738T1 (de)
AU (3)	AU2004215672B2 (de)
BR (3)	BRPI0407758A (de)
CA (3)	CA2516620A1 (de)
CL (2)	CL2004000392A1 (de)
CO (2)	CO5690580A2 (de)
DE (4)	DE10308355A1 (de)
DK (3)	DK1599453T3 (de)
EC (2)	ECSP055985A (de)
ES (3)	ES2329366T3 (de)
HR (3)	HRP20050744A2 (de)
IL (2)	IL170314A (de)
MA (3)	MA27736A1 (de)
MX (3)	MXPA05008988A (de)
NO (3)	NO20054398L (de)
OA (2)	OA13035A (de)
PA (1)	PA8596801A1 (de)
PE (3)	PE20050292A1 (de)
PL (3)	PL378130A1 (de)
PT (3)	PT1599453E (de)
RS (1)	RS20050594A (de)
RU (3)	RU2005129992A (de)
SA (1)	SA04250153A (de)
TN (2)	TNSN05204A1 (de)
TW (3)	TW200508210A (de)
UY (2)	UY28209A1 (de)
WO (3)	WO2004076428A1 (de)
ZA (2)	ZA200505765B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7576131B2 (en) *	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) *	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) *	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
WO2007039177A2 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
KR101398715B1 (ko)	2006-08-10	2014-05-27	가부시키가이샤 미모잭스	아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
EP2181087B1 (de)	2007-08-16	2015-10-14	Solvay Sa	Verfahren zur herstellung von estern von 4-fluor-substituierten 3-oxoalkansäuren
PT2246343T (pt) *	2008-02-29	2016-08-05	Nissan Chemical Ind Ltd	Processo de produção de composto de tiofeno e seu intermediário
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
CN116414014A (zh)	2017-12-13	2023-07-11	佳能株式会社	盒与图像形成装置
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) *	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en)	1993-02-15	1995-08-14	Wellcome Found	Hypolipidaemic compounds
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs)	1996-01-17	1998-11-11	Novo Nordisk A/S	Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
DE69737479T4 (de)	1996-08-30	2010-05-06	Novo Nordisk A/S	Glp-1 derivate
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
RU2200161C2 (ru)	1996-12-31	2003-03-10	Др. Редди'З Рисерч Фаундейшн	Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
KR20010021936A (ko)	1997-07-16	2001-03-15	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) *	1998-03-10	2010-01-21	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
EP1108713A4 (de) *	1998-08-27	2006-04-05	Ono Pharmaceutical Co	Carbonsäurederivate und sie als aktiven bestandteil enthaltende medikamente
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) *	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
WO2000063208A1 (en)	1999-04-16	2000-10-26	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
DE60035682T2 (de)	1999-04-28	2008-04-30	Sanofi-Aventis Deutschland Gmbh	Di-aryl-säurederivate als ppar rezeptor liganden
DE60027420T2 (de) *	1999-04-28	2006-11-16	Aventis Pharma Deutschland Gmbh	Tri-aryl-säurederivate als ppar rezeptor liganden
US6284766B1 (en)	1999-04-30	2001-09-04	Neurogen Corporation	9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
US6399640B1 (en)	1999-06-18	2002-06-04	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2001004146A2 (en)	1999-07-09	2001-01-18	Cohesion Technologies, Inc.	Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
EP1204654B1 (de)	1999-07-29	2003-07-23	Eli Lilly And Company	Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
CA2383781A1 (en) *	1999-09-01	2001-03-08	Aventis Pharma Deutschland Gmbh	Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en)	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
WO2001040171A1 (en)	1999-12-03	2001-06-07	Astrazeneca Ab	Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
ATE419036T1 (de)	2000-03-31	2009-01-15	Prosidion Ltd	Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention
EP1277745A4 (de)	2000-04-25	2004-09-15	Kyorin Seiyaku Kk	Neue stabile kristalle von thiazolidindion-derivaten und verfahren zu ihrer herstellung
DK1277736T3 (da)	2000-04-28	2007-10-01	Asahi Kasei Pharma Corp	Hidtil ukendte bicykliske forbindelser
JP2004507456A (ja)	2000-05-11	2004-03-11	ブリストル−マイヤーズ　スクイブ　カンパニー	成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
CA2410597A1 (en)	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
DK1294682T3 (da)	2000-06-09	2004-08-02	Aventis Pharma Gmbh	Acylphenylurinstofderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (de) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Verfahren zum Identifizieren von Verbindungen, die die Ubiquitin vermittelte Proteolyse von IkB inhibieren
ES2288982T3 (es)	2000-08-23	2008-02-01	Eli Lilly And Company	Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
KR20030027054A (ko) *	2000-08-23	2003-04-03	일라이 릴리 앤드 캄파니	옥사졸릴-아릴프로피온산 유도체 및 ｐｐａｒ효능제로서의 그의 용도
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja)	2000-12-05	2004-04-08	杏林製薬株式会社	置換カルボン酸誘導体
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
IL156550A0 (en)	2000-12-21	2004-01-04	Aventis Pharma Gmbh	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
ATE370130T1 (de) *	2000-12-25	2007-09-15	Ono Pharmaceutical Co	Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
BR0207285A (pt) *	2001-02-15	2004-02-10	Pfizer Producs Inc	Agonistas de ppar
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
ES2275887T3 (es) *	2001-06-07	2007-06-16	Eli Lilly And Company	Moduladores de receptores activados por proliferadores de peroxisoma (ppar).
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003004458A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	New compounds
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
DK1425014T3 (da)	2001-08-31	2007-04-10	Sanofi Aventis Deutschland	Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
ATE433440T1 (de)	2002-02-05	2009-06-15	Lilly Co Eli	Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en)	2002-07-09	2004-01-15	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de active Application Filing
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Application Discontinuation
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Application Discontinuation
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Application Discontinuation
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de active IP Right Grant
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de active Application Filing
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en active Active
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2329366T3 (es)	2009-11-25
US20080167354A1 (en)	2008-07-10
DK1599455T3 (da)	2009-11-09
ES2287700T3 (es)	2007-12-16
DE10308355A1 (de)	2004-12-23
BRPI0407758A (pt)	2006-02-14
KR20050105492A (ko)	2005-11-04
PT1599453E (pt)	2009-07-14
US7335671B2 (en)	2008-02-26
CN1756748A (zh)	2006-04-05
JP2006519194A (ja)	2006-08-24
DK1599453T3 (da)	2009-08-24
AU2004215673A1 (en)	2004-09-10
CN1753879A (zh)	2006-03-29
TNSN05204A1 (en)	2007-06-11
MXPA05008988A (es)	2005-10-18
US20080015238A1 (en)	2008-01-17
ZA200505765B (en)	2006-05-31
NO20054398L (no)	2005-11-02
CO5690578A2 (es)	2006-10-31
US20040209920A1 (en)	2004-10-21
CN100439347C (zh)	2008-12-03
HRP20050744A2 (en)	2006-09-30
RU2005129995A (ru)	2006-01-27
US7872034B2 (en)	2011-01-18
MA27736A1 (fr)	2006-02-01
CA2517386A1 (en)	2004-09-10
WO2004076427A1 (de)	2004-09-10
BRPI0407814A (pt)	2006-02-14
OA13035A (en)	2006-11-10
US20050101637A1 (en)	2005-05-12
WO2004076428A1 (de)	2004-09-10
ATE430738T1 (de)	2009-05-15
TW200500349A (en)	2005-01-01
US7365084B2 (en)	2008-04-29
JP2006519199A (ja)	2006-08-24
ATE365159T1 (de)	2007-07-15
AR043432A1 (es)	2005-07-27
RS20050594A (en)	2007-12-31
DE502004004139D1 (de)	2007-08-02
SA04250153A (ar)	2005-12-03
PE20050293A1 (es)	2005-05-24
ECSP055986A (es)	2006-01-16
PE20040959A1 (es)	2005-01-17
PL378437A1 (pl)	2006-04-03
CL2004000391A1 (es)	2005-01-07
DK1599452T3 (da)	2007-10-01
EP1599455B1 (de)	2009-07-01
AU2004215677B2 (en)	2010-01-07
AU2004215677A1 (en)	2004-09-10
AU2004215672A1 (en)	2004-09-10
CN1753881A (zh)	2006-03-29
KR20050106462A (ko)	2005-11-09
EP1599453A1 (de)	2005-11-30
UY28210A1 (es)	2004-09-30
EP1599453B1 (de)	2009-05-06
US20050215596A1 (en)	2005-09-29
CA2516620A1 (en)	2004-09-10
NO20054396D0 (no)	2005-09-22
PL377735A1 (pl)	2006-02-20
NO20054396L (no)	2005-11-11
TNSN05206A1 (en)	2007-06-11
US7259177B2 (en)	2007-08-21
ATE435217T1 (de)	2009-07-15
NO20054408D0 (no)	2005-09-22
AU2004215672B2 (en)	2010-01-07
WO2004076426A1 (de)	2004-09-10
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
TW200508210A (en)	2005-03-01
CL2004000392A1 (es)	2005-04-22
DE502004009690D1 (de)	2009-08-13
BRPI0407907A (pt)	2006-02-14
CA2517381A1 (en)	2004-09-10
PT1599455E (pt)	2009-09-29
ECSP055985A (es)	2006-01-16
HRP20050742A2 (en)	2006-09-30
JP2006519193A (ja)	2006-08-24
PT1599452E (pt)	2007-09-12
CN100398526C (zh)	2008-07-02
MXPA05008951A (es)	2005-11-04
EP1599452A1 (de)	2005-11-30
UY28209A1 (es)	2004-09-30
PL378130A1 (pl)	2006-03-06
EP1599455A1 (de)	2005-11-30
MXPA05008995A (es)	2005-10-18
EP1599452B1 (de)	2007-06-20
KR20050106461A (ko)	2005-11-09
MA27742A1 (fr)	2006-02-01
AR043427A1 (es)	2005-07-27
CN100439345C (zh)	2008-12-03
CO5690580A2 (es)	2006-10-31
OA13034A (en)	2006-11-10
MA27737A1 (fr)	2006-02-01
IL170314A (en)	2010-11-30
AR043433A1 (es)	2005-07-27
AU2004215673B2 (en)	2009-10-01
ZA200505768B (en)	2005-11-23
RU2005129992A (ru)	2006-02-10
TW200510352A (en)	2005-03-16
RU2005130002A (ru)	2006-01-27
ES2326418T3 (es)	2009-10-09
NO20054398D0 (no)	2005-09-22
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
PE20050292A1 (es)	2005-05-24

Legal Events

Date	Code	Title	Description
2010-05-27	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE502004009453D1 (de)	2009-06-18	3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
ATE410430T1 (de)	2008-10-15	2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE449604T1 (de)	2009-12-15	Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
DE502005006955D1 (de)	2009-05-07	N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-bernsteinsäureamid derivate und verwandte verbindungen als ppar-liganden (peroxisomen-proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidämie und diabetes
ATE327753T1 (de)	2006-06-15	Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
DE602005004268D1 (de)	2008-02-21	1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenylpropan-2-olderivate und verwandte verbindungen als modulatoren der norepinephrin-(ne-) und der serotonin-(5-ht-) aktivität und der monoaminwiederaufnahme zur behandlung von vasomotorischen symptomen (vms)
DE602005026984D1 (de)	2011-04-28	Chinolin-derivate zur behandlung von latenter tuberkulose
DE602004020674D1 (de)	2009-05-28	1-benzoyl-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DE602006017980D1 (de)	2010-12-16	3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE504580T1 (de)	2011-04-15	Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
DE502005002310D1 (de)	2008-01-31	Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes
DE602004002394D1 (de)	2006-10-26	(3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
DE602006005640D1 (de)	2009-04-23	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE602005005298D1 (de)	2008-04-24	1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-chinazolin-2-on-derivate und die jeweiligen 1h-benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erk
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE345340T1 (de)	2006-12-15	N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
DE602006002608D1 (de)	2008-10-16	4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE525355T1 (de)	2011-10-15	1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
DE602004022153D1 (de)	2009-09-03	Verbindungen zur behandlung von obesitas
DE602004006118D1 (de)	2007-06-06	2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE530525T1 (de)	2011-11-15	Piperidine und verwandte verbindungen zur behandlung von demenz
DE602004014955D1 (de)	2008-08-21	1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)-ethylcyclohexanol-derivate als monoamin-wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ATE519740T1 (de)	2011-08-15	Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
ATE343571T1 (de)	2006-11-15	4-ä'3-(sulfonylamino)phenyl)'1- (cyclymethyl)piperidin-4- ylidene)methylübenzamidederivate als delta-opioid-rezeptorliganden zur behandlung von schmerzen, angstzuständen und funktionellen gastrointestinalen erkrankungen
DE602004003829D1 (de)	2007-02-01	2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit